Hologic has completed its purchase of San Diego cancer testing company Biotheranostics, Inc., the Marlborough medical technology company announced late Monday.
Biotheranostics is a San Diego firm specializing in molecular diagnostic tests for breast and metastatic cancer, according to a press release from Hologic.
“We are even more excited about the acquisition because last month the National Comprehensive Cancer Network revised its clinical practice guidelines to include Breast Cancer Index as the only gene expression assay to predict benefit from extended endocrine therapy for patients with early-stage hormone-receptor positive breast cancer,” said Kevin Thornal, president of Hologic’s diagnostic solutions division, in a statement.
The impending $230-million acquisition was first announced in early January, the third Hologic acquisition in five months.
The other two acquisitions included a $64-million purchase of German-based biopsy firm SOMATEX Medical Technologies GmbH, also announced in January, and an $80-million acquisition of Texas-based Acessa Health, announced in August.
